Overview

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Status:
Unknown status

Trial end date:
2020-05-01

Target enrollment:

Participant gender:

Summary

The investigators postulated that the exploitation of the pro-immunogenic effects of radiotherapy with thymosin might result in abscopal responses among patients with metastatic cancer. The research is designed to evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy combined with thymosin alpha 1. An exploratory biomarker analysis in blood and tumor samples is also planned.

Phase:

Phase 2

Details

Lead Sponsor:

First People's Hospital of Hangzhou

Treatments:

Erlotinib Hydrochloride
Gefitinib
Thymalfasin